Recurrence Clinical Trials

20 recruiting

Recurrence Trials at a Glance

93 actively recruiting trials for recurrence are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Not Applicable with 35 trials, with the heaviest enrollment activity in Beijing, Nanjing, and Barcelona. Lead sponsors running recurrence studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Amsterdam UMC, location VUmc, and Chang Gung Memorial Hospital.

Browse recurrence trials by phase

Treatments under study

About Recurrence Clinical Trials

Looking for clinical trials for Recurrence? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrence trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrence clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 93 trials

Recruiting
Phase 2

Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRelapse/Recurrence
Shenzhen University General Hospital10 enrolled1 locationNCT07563179
Recruiting

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

CancerSurvivorshipRecurrent+2 more
Memorial Sloan Kettering Cancer Center1,000 enrolled4 locationsNCT07030686
Recruiting
Not Applicable

The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma

RecurrenceChronic Subdural Hematoma
Huashan Hospital830 enrolled1 locationNCT06401772
Recruiting
Phase 3

FMT Capsules for rCDI

FMTClostridioides Difficile Infection Recurrence
Helsinki University Central Hospital76 enrolled1 locationNCT07458984
Recruiting
Phase 3

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Clostridium Difficile Infection RecurrenceClostridium DifficileClostridioides Difficile Infection+7 more
Vedanta Biosciences, Inc.852 enrolled215 locationsNCT06237452
Recruiting
Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Neoplasm MetastasisEndometrial NeoplasmsNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute30 enrolled1 locationNCT06532539
Recruiting
Phase 2

Study of Lacutamab in Peripheral T-cell Lymphoma

Relapse/RecurrencePeripheral T Cell Lymphoma
The Lymphoma Academic Research Organisation56 enrolled64 locationsNCT04984837
Recruiting
Phase 3

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Acute Myeloid LeukemiaRelapse/Recurrence
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS339 enrolled47 locationsNCT06713837
Recruiting
Phase 2Phase 3

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Prostate CancerMetastatic Prostate CancerOligometastasis+3 more
VA Office of Research and Development464 enrolled20 locationsNCT04787744
Recruiting
Phase 2

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Locoregional Recurrence
Oana Danciu200 enrolled20 locationsNCT05467891
Recruiting

Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer

Renal Cell Carcinoma (Kidney Cancer)Fear of Cancer Recurrence
Brigitta Rasmussen Villumsen105 enrolled3 locationsNCT07234656
Recruiting
Not Applicable

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

BRCA2 MutationFear of Cancer RecurrenceBreast Cancer Susceptibility Gene (BRCA1) Mutation
CHU de Quebec-Universite Laval250 enrolled1 locationNCT06817694
Recruiting
Not Applicable

NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks

Stroke RecurrenceStroke (CVA) or TIA
Hospital Universitari Vall d'Hebron Research Institute250 enrolled1 locationNCT07500116
Recruiting
Not Applicable

Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

Prostate AdenocarcinomaOligorecurrenceIliac Nodal Disease+2 more
University Health Network, Toronto26 enrolled1 locationNCT06831032
Recruiting

Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation

Clostridioides Difficile Infection Recurrence
Fondazione Policlinico Universitario Agostino Gemelli IRCCS20 enrolled1 locationNCT05739825
Recruiting
Phase 3

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Bladder CancerUrothelial Carcinoma BladderNeoplasm Recurrence+3 more
Verity Pharmaceuticals Inc.540 enrolled6 locationsNCT05037279
Recruiting

PROCARE - PROstate Cancer Real World Evidence Registry

Prostate CancerNon-metastatic Castration-resistant Prostate CancerBiochemical Recurrence of Malignant Neoplasm of Prostate
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Phase 1

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

OsteosarcomaPulmonary Recurrence of Osteosarcoma
Emory University12 enrolled1 locationNCT06492954
Recruiting
Not Applicable

Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography

Breast CancerBreast Cancer RecurrencePost Treatment Surveillance
Royal College of Surgeons, Ireland400 enrolled1 locationNCT07443579
Recruiting

Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer

Bladder CancerBladder Cancer RecurrenceAdjuvant Therapy for Bladder Cancer+1 more
Zhilong Dong400 enrolled1 locationNCT07424560